251 related articles for article (PubMed ID: 26022529)
1. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
[TBL] [Abstract][Full Text] [Related]
2. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
[TBL] [Abstract][Full Text] [Related]
3. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
French SL; Arthur JF; Tran HA; Hamilton JR
Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
[TBL] [Abstract][Full Text] [Related]
4. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
Storey RF; Kotha J; Smyth SS; Moliterno DJ; Rorick TL; Moccetti T; Valgimigli M; Dery JP; Cornel JH; Thomas GS; Huber K; Harrington RA; Hord E; Judge HM; Chen E; Strony J; Mahaffey KW; Tricoci P; Becker RC; Jennings LK
Thromb Haemost; 2014 May; 111(5):883-91. PubMed ID: 24402559
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia.
Schoergenhofer C; Schwameis M; Gelbenegger G; Buchtele N; Thaler B; Mussbacher M; Schabbauer G; Wojta J; Jilma-Stohlawetz P; Jilma B
Thromb Haemost; 2018 Jul; 118(7):1176-1184. PubMed ID: 29864779
[TBL] [Abstract][Full Text] [Related]
6. Vorapaxar for the reduction of atherothrombotic events.
Diaz-Ricart M; Escolar G
Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
[TBL] [Abstract][Full Text] [Related]
7. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
Bhandari B; Mehta B
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
[TBL] [Abstract][Full Text] [Related]
8. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
Cheng JW
Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol-Rich Microdomains Contribute to PAR1 Signaling in Platelets Despite a Weak Localization of the Receptor in These Microdomains.
Rabani V; Lagoutte-Renosi J; Series J; Valot B; Xuereb JM; Davani S
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138025
[TBL] [Abstract][Full Text] [Related]
10. Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist.
Spoerri PM; Kato HE; Pfreundschuh M; Mari SA; Serdiuk T; Thoma J; Sapra KT; Zhang C; Kobilka BK; Müller DJ
Structure; 2018 Jun; 26(6):829-838.e4. PubMed ID: 29731231
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
[TBL] [Abstract][Full Text] [Related]
12. Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation.
Friebel J; Moritz E; Witkowski M; Jakobs K; Strässler E; Dörner A; Steffens D; Puccini M; Lammel S; Glauben R; Nowak F; Kränkel N; Haghikia A; Moos V; Schutheiss HP; Felix SB; Landmesser U; Rauch BH; Rauch U
Cells; 2021 Dec; 10(12):. PubMed ID: 34944024
[TBL] [Abstract][Full Text] [Related]
13. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Arif SA; D'Souza J; Gil M; Gim S
Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
[TBL] [Abstract][Full Text] [Related]
14. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
Ghosal A; Lu X; Penner N; Gao L; Ramanathan R; Chowdhury SK; Kishnani NS; Alton KB
Drug Metab Dispos; 2011 Jan; 39(1):30-8. PubMed ID: 20926621
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
16. The antithrombotic effect of aprotinin: actions mediated via the proteaseactivated receptor 1.
Poullis M; Manning R; Laffan M; Haskard DO; Taylor KM; Landis RC
J Thorac Cardiovasc Surg; 2000 Aug; 120(2):370-8. PubMed ID: 10917956
[TBL] [Abstract][Full Text] [Related]
17. Entry from the Lipid Bilayer: A Possible Pathway for Inhibition of a Peptide G Protein-Coupled Receptor by a Lipophilic Small Molecule.
Bokoch MP; Jo H; Valcourt JR; Srinivasan Y; Pan AC; Capponi S; Grabe M; Dror RO; Shaw DE; DeGrado WF; Coughlin SR
Biochemistry; 2018 Oct; 57(39):5748-5758. PubMed ID: 30102523
[TBL] [Abstract][Full Text] [Related]
18. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
[TBL] [Abstract][Full Text] [Related]
19. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
20. Vorapaxar in the secondary prevention of atherothrombosis.
Tantry US; Liu F; Chen G; Gurbel PA
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
